Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The Need for Continuing Vigilance: Addressing the Threat for Transmission of Blood-Borne Infectious Disease

Samuel L. Stanley, Jr

As international travel and human encroachment into previously isolated areas have increased, so too has the potential for the emergence of new infectious diseases. Populations likely to be susceptible to new infectious diseases have also increased in size. The past three decades have seen outbreaks of diseases caused by parvoviruses, Nipah virus, circoviruses, and prions. Infectious pathogens such as these are formidable opponents; they can adapt to new hosts or cause variant diseases within new hosts. Many are also resistant to current inactivation techniques. In order to prevent or contain outbreaks, pathogens that emerge must be identified quickly and efficiently; research and ongoing global surveillance are therefore of primary importance. To effectively protect the blood supply and blood-based therapies, this research should include investigations into improved techniques for detection, screening, and viral inactivation, as well as into ways to reduce patient exposure to infectious pathogens via therapeutic agents. The proactive devotion of appropriate resources to infectious disease containment and prevention prior to an epidemic should be perceived as both essential public health policy and cost effective.

In the wake of the significant strides in vaccines and antibiotics that followed World War II, most of the public health community believed that infectious diseases could be effectively controlled. By the 1990s, however, as new infectious pathogens emerged, public health experts could no longer believe that the threat of infectious diseases had receded. In fact, the potential for the emergence of new infectious diseases was increasing, a result of commonplace and extensive international travel and steady human encroachment into previously isolated areas.

Infectious diseases are categorized as “emerging” based on either their documented increased incidence in humans over the past two decades or on evidence of their potential to increase in the near future. Such evidence would include reports of a pathogen’s demonstrated ability to increase its host range by jumping species to infect new populations. Emerging infectious pathogens in recent decades have included human immunodeficiency virus (HIV), avian/variant influenza, severe acute respiratory syndrome (SARS) virus, West Nile virus, dengue fever, monkeypox, parvovirus, Nipah virus, Ebola virus, and variant Creuzfeldt-Jakob disease (vCJD). Not all infectious diseases are a threat to the blood supply, because the clinical presentation associated with many infectious diseases is severe enough that infected patients are not likely to be blood donors. For example, the Ebola virus is blood-borne, but infected persons are not likely to donate blood because they become ill very quickly. However, other infectious diseases, such as HIV and vCJD, have long latent infectious periods during which persons can donate blood with no knowledge that they are infected. These latter types of infectious diseases as well as others with mild clinical sequelae have the potential to infect the blood supply through donation and be transmitted to the hemophilia community and other persons through blood products (Figure 1).

There are multiple arguments to support a belief in the inevitability of the emergence of additional infectious diseases, principally reflecting the following five factors:

- Adaptability of viruses allows for viral mutations that enable defensive or aggressive adaptation to new environments, promoting development of drug resistance or achievement of cross-species transmission
- Human encroachment into previously unexplored habitats increases exposure to new agents
Patterns in New Zoonotic Infections

\[\text{Figure 1} \quad \text{Infectious diseases have different potential impact on the blood supply. Figure courtesy of Dr David On-}\]

- Increases in the numbers of susceptible hosts (eg, elderly, HIV-infected, or chemotherapy patients) offer greater opportunities for infectious pathogen disease transmission\(^2\)
- Advances in pathogen screening technologies have resulted in increased sensitivity and, as a result, better detection of novel (or previously unrecognized) pathogens
- Currently unknown biological factors that may become evident in the future (referred to as the “X-factor”).

Specific Pathogen Threats

Paroviruses

Paroviruses are non–lipid-enveloped, single-stranded DNA viruses that prefer to infect and lyse rapidly dividing cells, and are a continuous viral threat.\(^3\) Currently, parovirus B19 (PVB19) is the only known pathogenic parovirus in humans,\(^4\) in whom it is capable of causing several diseases. PVB19 typically causes a self-limiting febrile illness, erythema infectiosum, also called slapped cheek syndrome or Fifth disease.\(^3\) However, in patients with immunosuppression or hematologic disorders, PVB19 can cause aplastic crises.\(^5\)

Paroviruses are potential threats to human health and safety because they can alter their host-specific proteins and effect cross-species transmission. Feline parovirus (FPLV), for example, which causes feline panleukopenia disease (ie, feline distemper), altered its host specificity, and in the mid to late 1970s there was an outbreak of a new disease in dogs with symptoms similar to feline distemper, including a high mortality rate.\(^3,6,7\) The most widely accepted hypothesis is that mutations in FPLV (or a closely related virus infecting mink or foxes) caused the emergence of a new virus, canine parovirus (CPV-2);\(^3\) essentially, FPLV jumped species. There was no natural resistance to CPV-2 in dogs and the result was a rapid global epidemic\(^3\) stopped within a year only by the development of a new vaccine for dogs and the use of the previously available cat vaccine.\(^7\)

The ability of paroviruses or related viruses to mutate and cross to humans is particularly alarming because they are difficult to eliminate. Parovirus and other non–lipid-enveloped viruses are highly resistant to the multiple viral inactivation protocols used in blood product processing, eg, pasteurization, heat treatment, and solvent/detergent techniques, that are effective against lipid-enveloped viruses.\(^8,9\) Parovirus contamination has been extensively documented in animal products such as tryp-
PVB19 can also be transmitted from asymptomatic blood donors and there are numerous reports of transmission through transfusion of virus-inactivated or purified clotting factor concentrates. Many of these cases have serious clinical consequences. PBV DNA has been found in virally attenuated plasma-derived clotting factors VIII (FVIII) and IX (FIX) and in first-generation recombinant FVIII (rFVIII) therapies. Contaminated human albumin used as a stabilizer was the most likely source for PBV DNA in these clotting factor therapies. PBV has also infected a patient who received a contaminated intravenous immune globulin infusion. Purification techniques, involving polymerase chain reaction (PCR) screening and removal of infected blood, reduce the presence of parvovirus in blood products but do not eliminate it entirely. As of yet, there have been no reports of the development of parvovirus disease subsequent to transfusion with any recombinant preparation, but the possibility has not been eliminated. Until more effective elimination techniques can be developed, there will always be the concern that animal- or human-derived products could serve as a source of transmission.

**Prions**

Prions are insoluble cellular protein particles that lack nucleic acid and, therefore, do not depend on genes or other factors for transmission of their traits. In humans, the prion protein gene (PRNP) on chromosome 20 usually encodes for a normal prion protein. In some instances, a post-translational conformational change occurs that creates an abnormal and transmissible particle, PrPSc, termed a prion. Prions are insoluble cellular protein particles that lack nucleic acid and, therefore, do not depend on genes or other factors for transmission of their traits. In humans, the prion protein gene (PRNP) on chromosome 20 usually encodes for a normal prion protein. In some instances, a post-translational conformational change occurs that creates an abnormal and transmissible particle, PrPSc, termed a prion. Prions are believed to be responsible in humans for at least five clinical diseases (Kuru, Gerstmann-Strassler-Scheinker disease, fatal familial insomnia, Creutzfeldt-Jakob disease [CJD], and variant CJD [vCJD]), prions are also present in other species. In animals prions cause scrapie, bovine spongiform encephalopathy (BSE or “mad cow” disease), chronic wasting disease, or feline encephalopathy. While prion diseases can develop spontaneously, they are more likely to be transmitted by dietary or blood-borne contamination; vCJD may be transmitted through consumption of contaminated meat or blood transfusion, while classical CJD has been transmitted by contaminated human pituitary hormones, dura matter drafts, corneal grafts, and surgical instruments. Given the characteristics of prions and their transmission, vCJD-associated prions present an alarming and real concern for all patients reliant on blood products, including patients with hemophilia.

As of December 2005, there have been 159 cases of vCJD reported worldwide. Although a majority of the cases have occurred in the United Kingdom, vCJD has also been identified in France, Ireland, Italy, the United States, and Canada. Patients with vCJD initially present with psychiatric symptoms such as depression, withdrawal, anxiety, cognitive impairment, and persistent painful sensory symptoms; eventually the symptoms progress to dementia and death. The median age at death is 28 years old, indicating that vCJD most frequently occurs in young people.

Susceptibility to vCJD, clinical symptoms of the disease, and the time to appearance of symptoms are determined by a polymorphism at codon 129 of the PRNP. Individuals who are heterozygous at codon 129 may be infected but still in the incubation period and, as a case report (detailed later) dem-
onstrates, vCJD can be transmitted while the patient is in the incubation period. Therefore, though the incidence of vCJD has been decreasing worldwide since 2000, latent infection may still be present, and the threat for transmission remains.

Blood transfusions are possibly responsible for two known cases of vCJD. In one case, a 62-year-old patient received a transfusion of red cells during surgery in 1996. One unit of the transfused blood was donated by a 24-year-old, who developed symptoms of vCJD 3 years and 4 months after the blood donation and died in 2000. In 2002, 6.5 years after the transfusion, the recipient manifested clinical symptoms of vCJD and died 13 months later. In the second case, an elderly patient received a transfusion of red blood cells in 1999. The blood donor developed symptoms of vCJD 18 months after the donation and died in 2001; vCJD was confirmed at autopsy. The recipient patient died 5 years after the transfusion, but showed no evidence of a neurologic disease. Nonetheless, postmortem, the patient was shown to be positive for vCJD.

In response to the vCJD threat, the United Kingdom announced that patients with hemophilia and other congenital bleeding disorders were at risk for vCJD, an announcement that has had notable financial and psychological impact, since patients with hemophilia and other congenital bleeding disorders who might be infected with vCJD are now considered capable of transmitting it to others. Therefore, the United Kingdom has implemented a new standard of care that includes disposal of those instruments used on patients with hemophilia that cannot be easily disinfected (eg, endoscopes, some dental equipment). This new standard of care is very costly, and some dentists are refusing to treat patients with hemophilia.

Other countries are also being forced to confront the spread of prion diseases. In October 2004, the French health ministry announced that a blood donor, who is still alive, had developed vCJD, and within a month French authorities announced discovery of blood donations by another individual later diagnosed with vCJD. The Belgian Red Cross used French-sourced plasma (from one infected donor) to produce factor VIII and IX in 1995 and 2002. Although as of yet there have been no reports of vCJD transmission in any person with hemophilia, it is clear that continued vigilance is necessary.

### Vigilance Is Expensive

Interventions to improve blood safety can be expensive. By comparing the cost of an intervention to the benefit given, the quality-adjusted-life year (QALY) can be calculated. To improve blood safety, the HIV antibody testing was developed and introduced in the mid 1980s. With 16 million transfusions each year in the United States, and an estimated prevalence of HIV of one in 10,000 blood donors, the cost per QALY for this intervention is calculated at $3,600. By contrast, the cost per QALY for p24 antigen testing for HIV is estimated at $2.3 million and for HIV NAT at $2.0 million. This difference in cost-effectiveness reflects the decreasing prevalence of HIV in the blood donor population. However, new defensive interventions could be very cost effective if (and when) a new blood-borne pathogen enters the blood supply (Figure 2). The costs of pathogen screening techniques must be considered in relation to the potential future costs for disease treatments in those who become infected. The medical costs associated with treatment of viral infections can be substantial: the costs involved in treating a patient with hemophilia co-infected with HIV are nearly 1.5 times greater than costs for those without co-infection.

Cost-effectiveness and cost-utility analyses are important for developing resource allocation decisions and many resources are used to ensure that transfusions of donated blood carry nearly “zero risk.” Economic evaluations of techniques for ensuring blood safety show that interventions may not be cost effective, but these conclusions have limited impact on developing blood policy decisions; society appears to accept that the value of protecting a nation’s blood supply from pathogen infection could transcend standard cost considerations. In addition, lessons appear to have been absorbed from the HIV epidemic, in which economics-based decisions could not control, and in fact inadvertently contributed to, the spread of the epidemic. Finally, policymakers fear litigation if their decisions with respect to infectious disease control are later shown to be irresponsible.

Continued vigilance may present a major financial burden, but is currently considered to be worthwhile in the face of the continuous emergence of new pathogens potentially transmissible through blood and blood products. It is important that this attitude be reinforced in the years to come, when the incidence of emerging pathogens is unlikely to diminish while the costs of pathogen control are likely to increase.
Addressing the Threat

Vigilance requires the establishment of a public health infrastructure that can operate appropriately in response to a crisis. This will need to include improved surveillance, constantly reviewed and updated to respond to emerging diseases. Since emerging pathogens occur worldwide, effective surveillance must be global. Currently the Centers for Disease Control and Prevention collaborates with the World Health Organization on surveillance and reporting of emerging infectious disease.

To ensure that emerging pathogens are identified quickly and efficiently, research into new technology is of primary importance. To be effective in protecting the blood supply and blood products these techniques should include improvement in detection, blood screening, and viral inactivation processes, as well as reducing exposure of patients to animal proteins capable of transmitting infectious pathogens.

Conclusion

Currently available hemophilia therapies have varying levels of exposure and vulnerability to contamination by blood-borne pathogens, reflecting the degree to which they incorporate components of human- or animal-derived plasma or albumin. Wherever possible, levels of vulnerability should be reduced, and those therapies with the least exposure to human- or animal-derived proteins, and therefore the lowest levels of vulnerability, should be made widely available.

Continued vigilance over the nation’s—and the world’s—blood supply is critical as long as infectious disease is a possibility, which is to say, far into the foreseeable future. Infectious pathogens are formidable opponents; they have the ability to change their genetic blueprint to adapt to new hosts or to cause variant diseases within new hosts. Globalization is increasing risks for pathogen emergence, and populations likely to be susceptible to new infectious diseases are growing in size. To proactively devote appropriate resources to infectious disease containment and prevention prior to an epidemic should be perceived as both essential public health policy and cost-effective.

References

1. Centers for Disease Control and Prevention (CDC): Preventing Emerging Infectious Diseases: A Strategy for the 21st Century. US Department of Health and Human Services. Atlanta, GA, Centers for Disease Control and Prevention, October 1998
2. Smolinski MS, Hamburg MA, Lederberg J (eds): Microbial Threats to Health: Emergence, Detection, and Response. National Institutes of Health. Washington, DC, National Academies Press, 2003
3. Ikeda Y, Nakamura K, Miyazawa T, Tohya Y, Takahashi E, Mochizuki M: Feline host range of canine parvovirus: Recent emergence of new antigenic types in cats. Emerg Infect Dis 8:341-346, 2002
4. Azzi A, Morfini M, Mannucci PM: The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 13:194-204, 1999
5. Hayakawa F, Imada K, Towatari M, Saito H: Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 118:1187-1189, 2002
6. Carpenter JL: Feline panleukopenia: Clinical signs and differential diagnosis. J Am Vet Med Assoc 158:837-839, 1971
7. Michigan Society for Medical Research (MISMR): Disease brochures. Available at: http://www.mismr.org/educational/parvo.html, accessed December 2005
8. Weimert T, Streichert S, Watson C, Gröner A: High-titer screening PCR: A successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 41:1500-1504, 2001
9. Morfini M, Azzi A, Mannucci PM: B19 parvovirus withstands “super heating” in antihemophilic concentrates. Thromb Haemost 76:821, 1996 (letter)
10. Croghan DL, Matchett A, Koski TA: Isolation of porcine parvovirus from commercial trypsin. Appl Microbiol 26:431-433, 1973
11. Coughenour K, Peay K, Haricz M, Beal G, Castaigne S, Leverger G, et al: Severe parvovirus B19 infection in an immunocompetent child with hemophilia A. Arch Pediatr 3:35-39, 1996
12. Yee TT, Cohen BJ, Pasit K, Lee CA: Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 93:457-459, 1996
13. Matsui H, Sugimoto M, Tsuji S, Shima M, Giddings J, Yoshio A: Transient hypoplastonic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate. J Pediatr Hematol Oncol 21:74-76, 1999
14. Koenigshuer UF, Eastlund T, Day JW: Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 40:1203-1206, 2000
15. Eis-Hubinger AM, Sosnowski U, Brackmann HH, Kaiser R, Matz B, Schneweis KE. Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products. J Pediatr Hematol Oncol 76:1120, 1996 (letter)
16. Eis-Hubinger AM, Sosnowski U, Brackmann HH: Parvovirus B19 DNA contamination in coagulation factor VIII products. Thromb Haemost 81:476-477, 1999
17. Abe H, Sugawara H, Hirayama J, Ihara H, Kato T, Ikeda H, et al: Removal of parvovirus B19 from hemoglobin solution by nanofiltration. Artif Cells Blood Subst Immobil Biotechnol 28:375-383, 2000
18. Wong KT, Shieh WJ, Zaki SR, Tan CT: Nipah virus infection, an emerging paramyxoviral zoonosis. Springer Semin Immunopathol 24:215-228, 2002
19. Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PS, Kiasiez TG, et al: Fatal encephalitis due to Nipah virus among pig farmers in Malaysia. Lancet 354:1257-1259, 1999
20. World Health Organization: Weekly Epidemiological Record 79:161-172, 2004
21. Chou C: Nipah’s return: The lethal “flying fox” virus may spread between people. Scientific American.com [serial online]. September 13, 2004. Available at: http://www.sciam.com/article.cfm?articleID=0006321E-8ECD-111B-87CB83414B7F0000&sc...
J. et al: Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363:417-421, 2004
29. The National Creutzfeldt-Jakob Disease Surveillance Unit: CJD statistics. Available at: http://www.cjd.ed.ac.uk/figures.htm, accessed December 2005
30. Health Protection Agency Communicable Disease Surveillance Centre: Incidence of Variant Creutzfeldt-Jakob Disease Onsets and Deaths in the UK January 1994-December 2004. Quarterly Report, January 19, 2005
31. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW: Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364:527-529, 2004
32. World Federation of Hemophilia (WFH): TSE Task Force bulletin on vCJD risk in U.K.-sourced plasma products. September 2004. Available at: http://www.hemophilia.ca/en/4.2.1.php, accessed December 2005
33. World Federation of Hemophilia (WFH): Update on vCJD and plasma products produced in France. December 14, 2004
34. AuBuchon JP, Birkmeyer JD, Busch MP: Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 37:45-51, 1997
35. Custer B: Economic analyses of blood safety and transfusion medicine interventions: A systematic review. Transfus Med Rev 18:127-143, 2004
36. Aledort LM: Economic aspects of haemophilia care. Haemophilia 5:216-219, 1999
37. Weinberg PD, Hounshell J, Sherman LA, Godwin J, Ali S, Tomori C, et al. Legal, financial, and public health consequences of HIV contamination of blood and blood products in the 1980s and 1990s. Ann Intern Med 136:312-319, 2002